Patient Survival USA Primary DD Pancreas Transplants 1/1/2004 – 12/31/2008 Categoryn 1Yr Surv. PTA 491 96.4% PAK1,136 96.6% SPK4,206 95.2% 2/09.

Slides:

Advertisements

Similar presentations

What makes a pancreas allograft marginal? Peter J Friend University of Oxford.

Advertisements

USRDS Clinical Indicators of Renal Allograft Loss Lawrence Y.C. Agodoa, MD FACP Jon J. Snyder, MS Bertram L. Kasiske, MD Allan J. Collins, MD FACP United.

Let’s get started. BETA CELL REPLACEMENT (PANCREAS AND ISLET TRANSPLANTATION) FOR THE TREATMENT OF DIABETES MELLITUS.

BACKGROUND ON PANCREAS HISTOLOGICAL FINDINGS: University of Maryland experience John C. Papadimitriou, M.D.,Ph.D. Professor of Pathology.

UK Renal Registry 16th Annual Report Figure 8.1. Trend in 1 year after 90 day incident patient survival by first modality, 2005–2011 cohort (adjusted to.

Summary of the 2012 ERA-EDTA Registry Annual Report Amsterdam, the Netherlands, 2014.

Table SA-1: Number of Kidney Transplants by Donor Type and Re-Transplant Status Source: Canadian Organ Replacement Register, 2014, CIHI *Missing data for.

Living Donor Kidney Transplant. What does the evidence say about outcome ? Professor Peter J Conlon.

© ANZOD Registry International Donor Statistics 1997 % of Multiple Organ Donors Donors PMP % Mult. Donors Eurotransplant:Germany, Austria, Belgium, Luxembourg,

Australian States Number of Donors Per Million Population Aust * NSW population excludes residents of the NSW Southern Area.

© ANZOD Registry Australian States Number of Donors Per Million Population Aust * NSW population excludes residents of the.

Living Donor Kidneys in PAK 2/11 USA Primary DD Pancreas Transplants 1/1/1988 – 12/31/2010.

International Pancreas Transplant Registry. Pancreas Transplants Pancreas Transplants 12/16/1966 – 12/31/2009 nUSA: n = 23,850 nNon USn = 11,365 1/10.

CM-1 Clinical Transplantation Lung Howard University Hospital Department of Transplantation Clive O. Callender, MD. Arturo Hernandez, MD.

David C. Mulligan, MD, FACS

BWGHF Liège Heart transplantation 2008.

CORR Report, 2012: CST Annual General Meeting S. Joseph Kim, MD, PhD, FRCPC Vice President, CORR Board of Directors Friday, February 24,

© ANZDATA Registry Method and Location of Dialysis 1453 (30%) 632 (13%) 1317 (27%) 1335 (27%) Number of Patients Australia 31-Dec-96.

1 Influence of donor & recipient risk factors and the choice of immunosuppression Long term outcome after renal transplantation Influence of donor & recipient.

Experiência Brasileira em Dessensibilizacão Pré-Transplante Renal. Maria Cristina Ribeiro de Castro Serviço de Transplante Renal e Laboratório de Imunologia.

When Using SRTR Slides. SRTR Slide Use Guidelines.

The Expanded Criteria Donors in Kidney Transplantation: 3 Years Experience FAM Shaheen, B. Al-Attar, MZ Souqiyyeh, J.E Cillo, A. Al Sayyari.

Transplantation in the Diabetic Patient The Status of Pancreas transplantation A. Osama Gaber Professor of Surgery Director of the Transplant Institute,

M ORNING R EPORT February 17, R ENAL T RANSPLANTS Most frequent transplant 45% of all pediatric transplants 7% of renal transplants ≤ 17y 3 year.

 Kidney  Pancreas  Liver  Heart 1954 by Murray/Harrison 1966 by Lillehei 1967 by Starzl 1968 by Barnard.

HEART-LUNG TRANSPLANTATION Adult Recipients JHLT Oct; 32(10):

2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 7: Transplantation.

Summary of the 2013 ERA-EDTA Registry Annual Report Amsterdam, the Netherlands, 2015.

Transplantation in HIV+ Recipients Ron Shapiro, M.D. THOMAS E. STARZL TRANSPLANTATION INSTITUTE UNIVERSITY OF PITTSBURGH.

HEART-LUNG TRANSPLANTATION Pediatric Recipients 2015 JHLT Oct; 34(10):

When Using SRTR Slides. SRTR Slide Use Guidelines.

Making the Most at the Margins Improving Organ Utilization and Recipient Outcomes. Jared C Brandenberger MD UNOS Region 6 Educational Forum March 6, 2015.

Impact of Recipient and Donor Non-immunological factors on the Outcome of Expanded Criteria Deceased Donors Kidney Transplantation Dr Hajar Al Hayyan.

Figures from Dialysis and kidney transplantation in Australia 1991–2010.

Liver transplantation for HCV infection R3 양 인 호 /Prof 김 병 호.

Draft Organ Allocation Criteria. Factors affecting Allocation Medical need Length of waiting time: time a illness progressed to a point when transplant.

New kidney offering scheme … Lorna Marson Deputy Chair, Kidney Advisory Group Work in progress.

United States Organ Transplantation SRTR & OPTN Annual Data Report, 2011 Kidney.

Heart Transplant Survival Based on Recipient and Donor Risk Scoring: A UNOS Database Analysis Jaimin R. Trivedi, Allen Cheng, Mickey Ising, Andrew Lenneman,

Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.

Kidney Graft Survival Rates do not improve by era: the impact of factor “Age” E. Bertoni MD, A. Larti MD, G. Rosso MD and M. Salvadori MD Renal Unit –

Pancreas Transplantation Committee

Number of transplants, by donor type figure 8.1

Number of Grafts Performed by Country

Volume 66, Issue 1, Pages (July 2004)

Volume 57, Issue 5, Pages (May 2000)

בטיחות בתעשייה בהיבט חברות הביטוח

EUROPEAN LIVER TRANSPLANT REGISTRY

Risk factors in deceased-donor transplants Risk factor 1988

ANZDATA Registry Annual Report 2013

The incidence of all cause graft failure, and death with a functioning graft was higher in patients who received a DCD donor transplant with total donor.

Pancreas Committee Spring 2017.

Organ transplantation: historical perspective and current practice

Mintu P. Turakhia et al. JACEP 2016;2:

Volume 68, Issue 5, Pages (November 2005)

Patient characteristics: American vs Canadian transplant patients

Christina L. Klein, MD, Daniel C. Brennan, MD, FACP

Arman Kilic, MD, Eric S. Weiss, MD, MPH, Jeremiah G

Impact of Diabetes Mellitus on the Association of Vascular Disease Before Transplantation With Long-term Transplant and Patient Outcomes After Kidney.

Stephen P. Mcdonald, Graeme R. Russ Kidney International

Volume 71, Issue 12, Pages (June 2007)

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

The risk of graft failure is highest for sex mismatched donors and recipients when the recipient body surface area is greater than the donor. The risk.

Kaplan-Meier estimated kidney graft and patient survival among patients with type 2 diabetes mellitus (T2DM), age 18–59 years, body mass index < 30 kg/m2.

Similar risk profiles for post-transplant renal dysfunction and long-term graft failure: UNOS/OPTN database analysis Nauman Siddiqi, Maureen A. McBride,

Orly Vardeny et al. JCHF 2016;4:

Number of Donors in Australia

Number of Donors in Australia

Presentation transcript:

Patient Survival USA Primary DD Pancreas Transplants 1/1/2004 – 12/31/2008 Categoryn 1Yr Surv. PTA % PAK1, % SPK4, % 2/09

Major Causes of Patient Death USA Primary DD Pancreas Transplants 1/1/2004 – 12/31/2008 SPK > 12 PAKPTA % Months Posttransplant 3/09

1-Year Patient Survival USA Primary DD Pancreas Transplants 1/1/2004 – 12/31/2008 3/08

Risk Factors for Patient Survival USA DD Primary Pancreas Transplants, 1/1/2004 – 12/31/2008 Risk Higher Lower

Pancreas Graft Function USA DD Primary Pancreas Transplants 1/1/2005 – 12/31/2009 3/10 Cat. n1Yr Fxn SPK 4,146 85% PAK94779% PTA46578% p <

Pancreas Graft Function USA DD Primary Pancreas Transplants 1/1/2004 – 12/31/2008 Cat. n1Yr Fxn PAK1, % PTA % SPK 4, % p < /09 DWFx Pancreas censored

Major Causes of Px Graft Failure USA Primary DD Pancreas Transplants 1/1/2004 – 12/31/2008 SPK 0-<3 3-<12 ≥ 12 PAKPTA % Months Posttransplant 3/09

1-Year Pancreas Graft Function USA DD Primary Pancreas Transplants 1/1/2000 – 12/31/2007 4/06

Hazard Ratio for Pancreas Graft Loss USA DD Primary Pancreas Transplants, 1/1/2000 – 12/31/2005 Risk Higher Lower PAK PTA Donor Age SPK

Hazard Ratio for Pancreas Graft Loss USA DD Primary Pancreas Transplants, 1/1/2000 – 12/31/2007 Risk Higher Lower

1-Year Pancreas Graft Function USA DD Primary Pancreas Transplants 1/1/2000 – 12/31/2006 4/08

1-Year Pancreas Graft Function USA DD Primary Pancreas Transplants 1/1/2000 – 12/31/2006 4/06

Hazard Ratio for Pancreas Graft Loss USA DD Primary Pancreas Transplants, 1/1/2000 – 12/31/2005 Risk Higher Lower PAKPTA Preservation Time [hrs] SPK

Technical Failure Rate USA DD Primary Pancreas Transplants 1/1/2000 – 12/31/2005 P = Donor Cause of Death

Graft Thrombosis Rate USA DD Primary Pancreas Transplants 1/1/2000 – 12/31/2005 P = Donor Cause of Death

Hazard Ratio for Technical Failure USA DD Primary Pancreas Transplants, 1/1/2000 – 12/31/2005 Risk Higher Lower PAKPTA Donor Age SPK

Hazard Ratio for Graft Thrombosis USA DD Primary Pancreas Transplants, 1/1/2000 – 12/31/2005 Risk Higher Lower PAKPTA Donor Age SPK

Hazard Ratio for Graft Thrombosis USA DD Primary Pancreas Transplants, 1/1/2000 – 12/31/2005 Risk Higher Lower

Immunological Pancreas Graft Loss USA Primary TS DD Pancreas Transplants 1/1/2004 – 12/31/2008 p = Cat. n 1Yr Loss PTA4456.0% PAK1,0165.5% SPK3,8792.1% 3/09

Even the Highest Risk Patients Do Better with a SPK than Remaining on the Waiting List UNOS Pancreas Waiting List 1/1/1995– 5/31/2003 2/04 University of Minnesota SPK Recipients